Galapagos, Servier deal

Galapagos received an undisclosed million milestone payment from Servier under a 2010 deal to discover and develop small molecules against undisclosed targets for osteoarthritis (OA). The payment was triggered by selection of the first preclinical candidate under the deal. Details were not disclosed. ...